Trials / Completed
CompletedNCT05518201
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
Evaluate the Safety and Immunogenicity of the 9-valent Human Papillomavirus Recombinant Vaccine (Hansenula Polymorpha) in Chinese Male Aged 9-45 Years: A Randomized, Blinded and Placebo-Controlled Phase I Study
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd. · Industry
- Sex
- Male
- Age
- 9 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the safety and tolerability of the 9vHPV vaccine in Chinese healthy male aged 9 to 45 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Placebo among 18-45 yrs | Subjects received 3 doses of placebo according to a 0, 2, 6-month schedule (0.5mL/each dose). |
| BIOLOGICAL | Placebo among 9-17 yrs | Subjects received 3 doses of placebo according to a 0, 2, 6-month schedule (0.5mL/each dose). |
Timeline
- Start date
- 2022-09-23
- Primary completion
- 2023-11-20
- Completion
- 2023-11-20
- First posted
- 2022-08-26
- Last updated
- 2024-04-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05518201. Inclusion in this directory is not an endorsement.